TARGESOME

Targesome, Inc.

Application Filed: 2001-01-04
Trademark Application Details
Trademark Logo TARGESOME

Mark For: TARGESOME™ trademark registration is intended to cover the categories of pharmaceutical preparations that aid in the transport and delivery of diagnostic, therapeutic and imaging agents for the treatment of tumor metastasis, solid tumor growth, osteoporosis, Paget's disease, humoral hyperglycemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy, macular degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis and smooth muscle cell migration, diseases associated with neovascular growth, namely, solid tumors, blood borne tumors, leukemia, tumor metastastasis, benign tumors, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, chronic inflammation, ocular angiogenic diseases, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation, diseases of excessive or abnormal stimulation of endothelial cells, namely, intestinal adhesions, atherosclerosis, restenosis, scleroderma, and hypertrophic scars. [all]

Status

2022-09-14 UTC
DEAD APPLICATION Refused Dismissed or Invalidated
This trademark application was refused, dismissed, or invalidated by the Office and this application is no longer active.


Research OneLook Acronym Finder
Serial Number76191699
Mark Literal ElementsTARGESOME
Mark Drawing Type1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S)
Mark TypeTRADEMARK
Standard Character ClaimNo
RegisterPRINCIPAL
Current LocationFILE REPOSITORY (FRANCONIA) 2004-07-15
Basis1(b)
Class StatusACTIVE
Primary US Classes
  • 006: Chemicals and Chemical Compositions
  • 018: Medicines and Pharmaceutical Preparations
  • 044: Dental, Medical and Surgical Appliances
  • 046: Foods and Ingredients of Foods
  • 051: Cosmetics and Toilet Preparations
  • 052: Detergents and Soaps
Primary International Class
  • 005 - Primary Class
  • (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed UseNo
Current UseNo
Intent To UseYes
Filed ITUYes
44D FiledNo
44E CurrentNo
66A CurrentNo
Current BasisNo
No BasisNo
Attorney NameTHOMAS D. BRATSCHUN
Attorney Docket Number39032-24001
Law Office AssignedM60
Employee NameFRENCH, CURTIS W

Timeline

2001-01-04Application Filed
2003-03-04Published
2003-03-04Published for Opposition
2004-05-28Abandon
2004-05-28Status: Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all docume
2004-05-28Status: Dead/Abandoned
2004-07-15Location: FILE REPOSITORY (FRANCONIA)
2018-07-08Transaction Date

Trademark Parties (Applicants & Owners)

Party: Targesome, Inc.
Address4030 Fabian Way Palo Alto, CALIFORNIA UNITED STATES 94303
Legal Entity TypeCorporation
Legal Entity StateDELAWARE

Documents

ApplicationIMAGE/TIFF2001-01-04
DrawingIMAGE/TIFF2001-01-04
Change of AddressIMAGE/TIFF2002-12-18
Notice of PublicationAPPLICATION/XML2003-02-12
Notice of AllowanceAPPLICATION/XML2003-05-16
Extension of Time to File SOU2003-11-24
ITU Extension Approval2003-12-05
Notice of Abandonment2004-07-09

Attorney of Record

THOMAS D. BRATSCHUN
SWANSON & BRATSCHUN, L.L.C.
1745 SHEA CENTER DRIVE, SUITE 330
HIGHLANDS RANCH CO 80129

Good, Services, and Codes

(ABANDONED)
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations that aid in the transport and delivery of diagnostic, therapeutic and imaging agents for the treatment of tumor metastasis, solid tumor growth, osteoporosis, Paget's disease, humoral hyperglycemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy, macular degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis and smooth muscle cell migration, diseases associated with neovascular growth, namely, solid tumors, blood borne tumors, leukemia, tumor metastastasis, benign tumors, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, chronic inflammation, ocular angiogenic diseases, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation, diseases of excessive or abnormal stimulation of endothelial cells, namely, intestinal adhesions, atherosclerosis, restenosis, scleroderma, and hypertrophic scars(ABANDONED)
IC 010. US 026 039 044. G & S: Medical devices, namely, polymerized nanoparticles for the transport and delivery of diagnostic, therapeutic and imaging agents

International Codes:5
U.S. Codes:006,018,044,046,051,052
International Codes:10
U.S. Codes:026,039,044
Type CodeType
GS0051Pharmaceutical preparations that aid in the transport and delivery of diagnostic, therapeutic and imaging agents for the treatment of tumor metastasis, solid tumor growth, osteoporosis, Paget's disease, humoral hyperglycemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy, macular degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis and smooth muscle cell migration, diseases associated with neovascular growth, namely, solid tumors, blood borne tumors, leukemia, tumor metastastasis, benign tumors, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, chronic inflammation, ocular angiogenic diseases, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation, diseases of excessive or abnormal stimulation of endothelial cells, namely, intestinal adhesions, atherosclerosis, restenosis, scleroderma, and hypertrophic scars

Trademark Filing History

DescriptionDateProceeding Number
ABANDONMENT - NO USE STATEMENT FILED2004-07-09
SOU EXTENSION 1 GRANTED2003-12-04
TEAS EXTENSION RECEIVED2003-11-24
SOU EXTENSION 1 FILED2003-11-24
NOA MAILED - SOU REQUIRED FROM APPLICANT2003-05-27
PUBLISHED FOR OPPOSITION2003-03-04
NOTICE OF PUBLICATION2003-02-12
APPROVED FOR PUB - PRINCIPAL REGISTER2002-12-23
EXAMINERS AMENDMENT MAILED2002-12-20
PREVIOUS ALLOWANCE COUNT WITHDRAWN2002-12-19
TEAS CHANGE OF CORRESPONDENCE RECEIVED2002-12-18
APPROVED FOR PUB - PRINCIPAL REGISTER2002-12-11
EXAMINERS AMENDMENT MAILED2002-12-06
ASSIGNED TO EXAMINER2002-12-0576419
PREVIOUS ALLOWANCE COUNT WITHDRAWN2002-10-08
ASSIGNED TO EXAMINER2002-10-0878190
ASSIGNED TO EXAMINER2002-10-0776419
APPROVED FOR PUB - PRINCIPAL REGISTER2002-09-27
ASSIGNED TO EXAMINER2002-09-0978190
REINSTATED2002-09-06
PETITION TO REVIVE-RECEIVED2002-06-10
CORRESPONDENCE RECEIVED IN LAW OFFICE2002-06-06
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE2002-05-27
NON-FINAL ACTION MAILED2001-05-24
ASSIGNED TO EXAMINER2001-05-0278190
ASSIGNED TO EXAMINER2001-04-2773363

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed